New FDA draft guidance seeks to clarify UDI forms

A new draft guidance from the U.S. Food and Drug Administration (FDA) aim to clarify how Unique Device Identifiers (UDIs) are included on medical devices.

“Unique Device Identification System: Form and Content of the Unique Device Identifier (UDI)” offers some detailed definitions of how the UDI has to be presented in both “both easily readable plain-text” and the form which can be transferred to an electronic health record or a computer system, known as automatic identification and data capture (AIDC).

For the text form, the guidance say the device identifier, production identifiers, and the data delimiters have to be included. The actual text of the UDI can be multiple lines, and “should be displayed below or near the AIDC technology form of the UDI.”

The AIDC instructions are a bit more complex. The draft guidance says while a particular AIDC system isn’t required, it does recommend the electronic form of the UDI come in some kind of scannable format, like a bar code. Since physical space on devices may be limited, the guidance allows for these codes to be broken up, such as a separate bar code for the device identifier and another for the production identifier.

Labelers could also include multiple types of scannable codes on a device.

The draft guidance also says the device identifier information should be listed before the production identifier, with any non-UDI information listed after the UDI.

Comments on the guidance will be accepted until September 24.  

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.